Article Details

Immune-Onc doses first subject in trial of IO-108 for HCC

Retrieved on: 2025-02-28 14:12:34

Tags for this article:

Click the tags to see associated articles and topics

Immune-Onc doses first subject in trial of IO-108 for HCC. View article details on hiswai:

Summary

The article describes a trial using IO-108 combined with atezolizumab and bevacizumab for treating hepatocellular carcinoma. This highlights business intelligence in developing advanced therapies, aligning with tags like antibodies, liver cancer, and Roche.

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up